[HTML][HTML] Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the …
CJ Lee, BN Savani, M Mohty, M Labopin… - …, 2017 - ncbi.nlm.nih.gov
Allogeneic blood or marrow hematopoietic cell transplantation continues to be the most
potent anti-leukemic treatment for adult patients with standard, high-risk, or chemo-refractory …
potent anti-leukemic treatment for adult patients with standard, high-risk, or chemo-refractory …
Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from …
CJ Lee, BN Savani, M Mohty, NC Gorin… - Bone marrow …, 2019 - nature.com
Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy generally
associated with poor prognosis. Allogeneic hematopoietic cell transplantation (alloHCT) …
associated with poor prognosis. Allogeneic hematopoietic cell transplantation (alloHCT) …
Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation
The use of anti-thymocyte globulin (ATG) has represented the standard of care in graft-
versus-host disease (GVHD) prophylaxis in patients undergoing a mismatched unrelated …
versus-host disease (GVHD) prophylaxis in patients undergoing a mismatched unrelated …
Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first …
S Yu, F Huang, Y Wang, Y Xu, T Yang, Z Fan, R Lin… - Leukemia, 2020 - nature.com
This study aimed to investigate graft-versus-leukemia (GVL) of haploidentical donor (HID)
compared with HLA-matched sibling donor (MSD) for high-risk acute myeloid leukemia (H …
compared with HLA-matched sibling donor (MSD) for high-risk acute myeloid leukemia (H …
Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT
N Shem-Tov, C Peczynski, M Labopin, M Itälä-Remes… - Leukemia, 2020 - nature.com
Unmanipulated haploidentical allogeneic stem cell transplantation (Allo-SCT) has become
an attractive alternative for patients lacking HLA-matched sibling or unrelated donors …
an attractive alternative for patients lacking HLA-matched sibling or unrelated donors …
Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a …
Abstract Whether to choose Haploidentical (Haplo) or one-antigen mismatched unrelated
donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant …
donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant …
Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis
RM Saliba, AM Alousi, J Pidala, M Arora… - … and cellular therapy, 2022 - Elsevier
Post-transplantation cyclophosphamide (PTCy) has been shown to effectively control graft-
versus-host disease (GvHD) in haploidentical (Haplo) transplantations. In this retrospective …
versus-host disease (GvHD) in haploidentical (Haplo) transplantations. In this retrospective …
Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute …
J Sanz, JE Galimard, M Labopin, B Afanasyev… - Journal of Hematology & …, 2021 - Springer
Background There is no information on the impact of donor type in allogeneic hematopoietic
stem cell transplantation (HCT) using homogeneous graft-versus-host (GVHD) prophylaxis …
stem cell transplantation (HCT) using homogeneous graft-versus-host (GVHD) prophylaxis …
A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia
S Piemontese, F Ciceri, M Labopin, W Arcese… - Journal of hematology & …, 2017 - Springer
Background In the absence of a HLA-matched related or matched unrelated donor,
allogeneic stem cell transplantation (allo-SCT) from mismatched unrelated donors or …
allogeneic stem cell transplantation (allo-SCT) from mismatched unrelated donors or …
[HTML][HTML] Posttransplantation cyclophosphamide-and sirolimus-based graft-versus-host-disease prophylaxis in allogeneic stem cell transplant
R Greco, F Lorentino, S Albanese… - … and Cellular Therapy, 2021 - Elsevier
Post-transplantation cyclophosphamide (PTCy) has emerged as a promising graft-versus-
host-disease (GVHD) prophylaxis in the setting of allogeneic hematopoietic stem cell …
host-disease (GVHD) prophylaxis in the setting of allogeneic hematopoietic stem cell …